Johnson & Johnson rescinded the company’s forecast for sales of its COVID-19 vaccine, as hesitancy in low income countries has led to a glut of supply of a shot once hoped to be the inoculation of choice for the developing world.
Boehringer Ingelheim Addresses Ukraine Crisis while Projecting 15 Launches by 2025
Blockbusters, Boehringer Ingelheim, Breakthrough Therapy Designation, Business, Eli Lilly, Fibrotic Diseases, Financials, Idiopathic Pulmonary Fibrosis (IPF), Launches, Pharma Companies, Product Launches, Product Pipeline, Product Pipelines, Product Pipelines, Quarterly results, R&D, R&D Investment Return, Russia invasion, SGLT2 Inhibitors, Therapeutics, UkraineBoehringer Ingelheim announced the company’s intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
Real Chemistry, a global health innovation company committed to making the world a healthier place for all, announced its 2021 business results. The company achieved revenue of $475 million, reflecting 36% growth for the full year compared to 2020.
Over the past six months, the Nasdaq Biotechnology Index has declined more than 20%. Some of the falling prices appear to be due to some investors losing interest in many companies that soared into favor during the COVID-19 pandemic. And these companies that have seen declining investor interest are now struggling to raise finances, according to BioSpace
Teva Pharmaceutical Industries Ltd. reported solid results for full-year 2021, posting $15.9 billion in revenue including a gain of $4.1 billion from the fourth quarter. The company recently settled an opioid-related case in Texas and is preparing to pay as much as $3.6 billion in cash and medicine to settle the lawsuits filed against Teva.
Merck & Co. expects the company’s 2022 sales to increase as much as 18 percent over 2021, mostly on sales of the new COVID-19 pill molnupiravir.
Massachusetts-based biotechnology firm Biogen and its Tokyo-based partner Eisai are seeking a speedy approval from the U.S. Food and Drug Administration for a second Alzheimer’s disease drug, lecanemab.
Novartis reported second-quarter 2021 financials with net sales growing 15 percent to $12.96 billion. The company also reported on its Covid-19 vaccine production with CureVac and some pipeline updates.
Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.
Merck & Co. Inc. said on April 29 the company would take a bigger hit to sales during 2021 than previously expected due to a resurgence in Covid-19 cases that has hurt demand for drugs that need to be given by doctors.